Author

LS Lauttia

Institutions: Mayo Clinic, University of Helsinki, Uppsala University Hospital, University of British Columbia, Nanostring Technologies (United States), Mayo Clinic in Florida

Observed institutions: Mayo Clinic, University of Helsinki, Uppsala University Hospital, University of British Columbia, Nanostring Technologies (United States), Mayo Clinic in Florida

OpenAlex ID: A5048225622

Abstract P3-11-05: Predictive gene signatures of adjuvant capecitabine benefit in triple negative breast cancer in the FinXX trial

2019 · S Chumsri, K Asleh, et al. · Cancer Research · 1

Works count: 1

Citation count: 1

H-index: 1

I10-index: